J&J Eyes $2.5 Billion from COVID Vaccines with Q2 Figures Better Than Expected
American multinational firm Johnson & Johnson forecasts revenues from its COVID-19 vaccine to reach $2.5 billion this year after second-quarter results came in better than expected, CNBC...